|
US147581A
(en)
*
|
|
1874-02-17 |
|
Improvement in combined corsets and bustles |
|
US3406178A
(en)
*
|
1964-02-04 |
1968-10-15 |
Monsanto Chem Australia Ltd |
Preparation of 2-substituted benzimidazoles
|
|
US3362956A
(en)
*
|
1965-08-19 |
1968-01-09 |
Sterling Drug Inc |
1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
|
|
US4200641A
(en)
*
|
1976-12-21 |
1980-04-29 |
Janssen Pharmaceutica, N.V. |
1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
|
|
IT1176613B
(it)
*
|
1984-08-14 |
1987-08-18 |
Ravizza Spa |
Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
|
|
GB8607294D0
(en)
*
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
|
HUT43600A
(en)
*
|
1985-06-22 |
1987-11-30 |
Sandoz Ag |
Process for production of new thiazole derivatives and medical compound containing those
|
|
GB8601160D0
(en)
*
|
1986-01-17 |
1986-02-19 |
Fujisawa Pharmaceutical Co |
Heterocyclic compounds
|
|
US5036088A
(en)
*
|
1986-06-09 |
1991-07-30 |
Pfizer Inc. |
Antiallergy and antiinflammatory agents, compositions and use
|
|
JPH0784462B2
(ja)
*
|
1986-07-25 |
1995-09-13 |
日清製粉株式会社 |
ベンゾイミダゾ−ル誘導体
|
|
US4968508A
(en)
*
|
1987-02-27 |
1990-11-06 |
Eli Lilly And Company |
Sustained release matrix
|
|
US4792452A
(en)
*
|
1987-07-28 |
1988-12-20 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation
|
|
GB8830312D0
(en)
*
|
1988-12-28 |
1989-02-22 |
Lundbeck & Co As H |
Heterocyclic compounds
|
|
US4954503A
(en)
*
|
1989-09-11 |
1990-09-04 |
Hoechst-Roussel Pharmaceuticals, Inc. |
3-(1-substituted-4-piperazinyl)-1H-indazoles
|
|
NZ241613A
(en)
*
|
1991-02-27 |
1993-06-25 |
Janssen Pharmaceutica Nv |
Highlighting intagliations in tablets
|
|
SE9100860D0
(sv)
*
|
1991-03-22 |
1991-03-22 |
Kabi Pharmacia Ab |
New use
|
|
IT1251144B
(it)
*
|
1991-07-30 |
1995-05-04 |
Boehringer Ingelheim Italia |
Derivati del benzimidazolone
|
|
US5225417A
(en)
*
|
1992-01-21 |
1993-07-06 |
G. D. Searle & Co. |
Opioid agonist compounds
|
|
FR2707294B1
(fr)
*
|
1993-07-06 |
1995-09-29 |
Pf Medicament |
Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
|
|
FR2727682A1
(fr)
*
|
1994-12-02 |
1996-06-07 |
Pf Medicament |
Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
|
|
US5883094A
(en)
*
|
1995-04-24 |
1999-03-16 |
Pfizer Inc. |
Benzimidazolone derivatives with central dopaminergic activity
|
|
US5854290A
(en)
*
|
1995-09-21 |
1998-12-29 |
Amy F. T. Arnsten |
Use of guanfacine in the treatment of behavioral disorders
|
|
US6083947A
(en)
*
|
1996-01-29 |
2000-07-04 |
The Regents Of The University Of California |
Method for treating sexual dysfunctions
|
|
US20040023948A1
(en)
*
|
1997-03-24 |
2004-02-05 |
Green Richard David |
Fast-dispersing dosage form containing 5-HT1 agonists
|
|
GB9706089D0
(en)
*
|
1997-03-24 |
1997-05-14 |
Scherer Ltd R P |
Pharmaceutical composition
|
|
SK284690B6
(sk)
*
|
1997-06-11 |
2005-09-08 |
The Procter And Gamble Company |
Ústna dávkovacia forma na zvýšenie ochrany horného tráviaceho traktu
|
|
FR2775188B1
(fr)
*
|
1998-02-23 |
2001-03-09 |
Lipha |
Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
|
|
EP0982030A3
(en)
*
|
1998-08-17 |
2000-05-10 |
Pfizer Products Inc. |
2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
|
|
US6680071B1
(en)
*
|
1999-03-03 |
2004-01-20 |
R. P. Scherer Technologies, Inc. |
Opioid agonist in a fast dispersing dosage form
|
|
IT1313625B1
(it)
*
|
1999-09-22 |
2002-09-09 |
Boehringer Ingelheim Italia |
Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
|
|
US6586435B2
(en)
*
|
2000-09-19 |
2003-07-01 |
Boehringer Ingelheim Pharma Kg |
Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
|
|
US6521623B1
(en)
*
|
2000-09-19 |
2003-02-18 |
Boehringer Ingelheim Pharma Kg |
N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
|
|
EP1256343B1
(en)
*
|
2001-05-11 |
2006-07-05 |
Jürgen K. Dr. Beck |
Flibanserin for the treatment of extrapyramidal movement disorders
|
|
US7183410B2
(en)
*
|
2001-08-02 |
2007-02-27 |
Bidachem S.P.A. |
Stable polymorph of flibanserin
|
|
US20030060475A1
(en)
*
|
2001-08-10 |
2003-03-27 |
Boehringer Ingelheim Pharma Kg |
Method of using flibanserin for neuroprotection
|
|
DE10138273A1
(de)
*
|
2001-08-10 |
2003-02-27 |
Boehringer Ingelheim Pharma |
Arzneimittel mit neuroprotektiver Wirkung
|
|
HUP0202719A3
(en)
*
|
2001-08-21 |
2006-01-30 |
Pfizer Prod Inc |
Pharmaceutical compositions for the treatment of female sexual dysfunctions
|
|
UA78974C2
(en)
*
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
|
US20040048877A1
(en)
*
|
2002-05-22 |
2004-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions containing flibanserin
|
|
US20040116532A1
(en)
*
|
2002-09-13 |
2004-06-17 |
Craig Heacock |
Pharmaceutical formulations of modafinil
|
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
|
US20050004105A1
(en)
*
|
2003-01-29 |
2005-01-06 |
Emer Leahy |
Treatment for a attention-deficit hyperactivity disorder
|
|
US20050037983A1
(en)
*
|
2003-03-11 |
2005-02-17 |
Timothy Dinan |
Compositions and methods for the treatment of depression and other affective disorders
|
|
US20050065158A1
(en)
*
|
2003-07-16 |
2005-03-24 |
Pfizer Inc. |
Treatment of sexual dysfunction
|
|
US20050239798A1
(en)
*
|
2004-04-22 |
2005-10-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for the treatment of premenstrual and other female sexual disorders
|
|
RU2445095C2
(ru)
*
|
2004-04-22 |
2012-03-20 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Новые фармацевтические композиции для лечения сексуальных расстройств
|
|
US20060014757A1
(en)
*
|
2004-07-14 |
2006-01-19 |
Boehringer Ingelheim Pharmaceuticals |
Method for the treatment of anorexia nervosa
|
|
US20060025420A1
(en)
*
|
2004-07-30 |
2006-02-02 |
Boehringer Ingelheimn International GmbH |
Pharmaceutical compositions for the treatment of female sexual disorders
|
|
WO2006096439A2
(en)
*
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
|
CA2599937A1
(en)
*
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
|
|
US20060211685A1
(en)
*
|
2005-03-04 |
2006-09-21 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of depression
|
|
EP1904182A2
(en)
*
|
2005-05-06 |
2008-04-02 |
Boehringer Ingelheim International GmbH |
Method for the treatment of drug abuse with flibanserin
|
|
US20060258640A1
(en)
*
|
2005-05-13 |
2006-11-16 |
Boehringer Ingelheim International Gmbh |
Use of Flibanserin in the treatment of chronic pain
|
|
JP2008540672A
(ja)
*
|
2005-05-19 |
2008-11-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
病状に起因する性的機能不全の治療方法
|
|
EP1888071A1
(en)
*
|
2005-05-19 |
2008-02-20 |
Boehringer Ingelheim International GmbH |
Method for the treatment of drug-induced sexual dysfunction
|
|
US20070123540A1
(en)
*
|
2005-10-29 |
2007-05-31 |
Angelo Ceci |
Sexual desire enhancing medicaments comprising benzimidazolone derivatives
|
|
US20070105869A1
(en)
*
|
2005-11-08 |
2007-05-10 |
Stephane Pollentier |
Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
|
|
EA200900264A1
(ru)
*
|
2006-08-14 |
2009-08-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Композиции флибансерина и способ их приготовления
|
|
CL2007002214A1
(es)
*
|
2006-08-14 |
2008-03-07 |
Boehringer Ingelheim Int |
Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
|
|
JP5220746B2
(ja)
*
|
2006-08-25 |
2013-06-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
制御放出システム及びその製造方法
|